一文速览:乳腺癌常用药物及治疗方案大盘点

2022-08-28 三叶草 MedSci原创

表格总结,方便查找!

点击下方链接,查看指南原文:

中国抗癌协会乳腺癌诊治指南与规范(2021年版)

乳腺癌诊疗指南2022

想查看更多乳腺癌指南?点击此处进入指南库!



乳腺癌是我国女性发病率及死亡率最高的几种癌症之一,并且其发病率呈逐年上升趋势。综合疗法是目前治疗乳腺癌的主要方法,常见治疗方法为手术治疗联合放疗、化疗、靶向治疗、免疫疗法、内分泌治疗等治疗手段。

近年来,随着对乳腺癌的研究的深入,乳腺癌的治疗手段也逐渐丰富,临床上可供选择的抗乳腺癌药物越来越多。在此,小编特地整理了乳腺癌常用的治疗药物及治疗方案,接下来就请各位看官跟着小编一起来学习一下吧!

一、乳腺癌治疗药物及作用机制

二、常见肿瘤化疗方案

参考文献:
[1] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10):954-1040.
[2] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2022[M]. 北京:人民卫生出版社, 2022:25-128.
[3] 药品说明书.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2085408, encodeId=538d20854083a, content=<a href='/topic/show?id=70f14863158' target=_blank style='color:#2F92EE;'>#常用药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48631, encryptionId=70f14863158, topicName=常用药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 15 02:47:51 CST 2023, time=2023-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905218, encodeId=bb311905218cd, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Mon Sep 26 18:47:51 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619243, encodeId=e6041619243e7, content=<a href='/topic/show?id=049148630cb' target=_blank style='color:#2F92EE;'>#常用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48630, encryptionId=049148630cb, topicName=常用药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Aug 30 02:47:51 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2085408, encodeId=538d20854083a, content=<a href='/topic/show?id=70f14863158' target=_blank style='color:#2F92EE;'>#常用药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48631, encryptionId=70f14863158, topicName=常用药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 15 02:47:51 CST 2023, time=2023-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905218, encodeId=bb311905218cd, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Mon Sep 26 18:47:51 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619243, encodeId=e6041619243e7, content=<a href='/topic/show?id=049148630cb' target=_blank style='color:#2F92EE;'>#常用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48630, encryptionId=049148630cb, topicName=常用药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Aug 30 02:47:51 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2085408, encodeId=538d20854083a, content=<a href='/topic/show?id=70f14863158' target=_blank style='color:#2F92EE;'>#常用药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48631, encryptionId=70f14863158, topicName=常用药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 15 02:47:51 CST 2023, time=2023-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905218, encodeId=bb311905218cd, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Mon Sep 26 18:47:51 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619243, encodeId=e6041619243e7, content=<a href='/topic/show?id=049148630cb' target=_blank style='color:#2F92EE;'>#常用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48630, encryptionId=049148630cb, topicName=常用药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Aug 30 02:47:51 CST 2022, time=2022-08-30, status=1, ipAttribution=)]

相关资讯

2022年浙江省家族遗传性肿瘤论坛

2022湘湖论坛,欢迎莅临

ESMO Open综述:“神药”光环下的阴影?T-Dxd相关ILD/肺炎发生率超15%!

ESMO Open:9项T-DXd单药治疗研究中药物相关间质性肺病和/或肺炎的汇总分析

European Radiology:乳腺癌成像与CEST MRI的首次尝试

葡萄糖胺(GlcN)是一种常用的葡萄糖类似物,具有良好的安全性。其通过葡萄糖转运器被肿瘤细胞吸收,然后进行磷酸化并在细胞内积累。

王涛教授:HER2阳性晚期乳腺癌治疗进展

我们一起跟随解放军总医院肿瘤医学部王涛教授对HER2阳性晚期乳腺癌治疗相关进展的文献回顾。

European Radiology:超声弹性成像在预测乳腺癌新辅助化疗后腋窝淋巴结状态中的应用

与传统的US相比,超声弹性成像(UE)可以提供有关组织硬度的额外信息,这与肿瘤的发生和疾病的发展关系密切。